>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

GKT137831

Setanaxib (GKT137831) | NADPH-oxidase 抑制剂 | 现货供应 | 美国品牌 | 免费采购电话400-668-6834

货号：
TK0534
规格：

2mg

5mg

10mg
价格：
￥0.00

产品参数

CAS No.	1218942-37-0
生物活性	Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.
分子式	C21H19ClN4O2
分子量	394.85
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder, -20°C ,3 years
溶解性数据	DMSO : 14.29 mg/mL (36.19 mM; Need ultrasonic)
体内研究	During the last half of CCl4 injections, some mice are treated with Setanaxib (GKT137831) daily. CCl4-induced liver fibrosis is more pronounced in SOD1mu compared to WT mice. Liver fibrosis in both SOD1mu and WT mice is attenuated by Setanaxib (GKT137831) treatment. The increased hepatic α-SMA expression is markedly decreased in SOD1mu mice treated with Setanaxib (GKT137831), to a level similar to that of WT mice given the NOX1/4 inhibitor.
体外研究	Setanaxib (GKT137831) is a potent Nox1/4 inhibitor (Kis=140±40/110±30 nM). Administration of Setanaxib (GKT137831) throughout the 72-hour period of normoxia or hypoxia exposure attenuates HPASMC proliferation under normoxic conditions at the 20 μM concentration but had no effect on proliferation in normoxic HPAECs. In the prevention paradigm, Setanaxib (GKT137831) attenuates hypoxia-induced HPASMC and HPAEC proliferation at 5 and 20 μM. Complementary assays of cell proliferation measuring the expression of PCNA or manual cell counting confirmed that Setanaxib (GKT137831) attenuates hypoxia-induced pulmonary vascular cell proliferation.
纯度及产品资料	98%

推荐产品